Compounds > lutetium
Page last updated: 2024-08-22

lutetium and Pancreatic Neoplasms

lutetium has been researched along with Pancreatic Neoplasms in 35 studies

Research

Studies (35)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (28.57)29.6817
2010's18 (51.43)24.3611
2020's7 (20.00)2.80

Authors

AuthorsStudies
Bagni, O; D'Agostini, A; Filippi, L; Pirisino, R1
Bartholomeusz, D; Bezak, E; Hsieh, W; Hull, A; Li, Y; Pukala, TL; Staudacher, AH; Tieu, W1
Baum, RP; Kulkarni, HR; Singh, A; Zhang, J1
Bodeker, KL; Bushnell, DL1
Martins, H; Moreira, AP; Silva, R; Soeiro, P1
Ercaliskan, A; Eskazan, AE; Kabasakal, L; Kucukyurt, S; Yagiz Ozogul, Y1
Leeuwenkamp, OR; Reed, N; Smith-Palmer, J; Virk, J1
Baum, RP; Klette, I; Kulkarni, HR; Osterkamp, F; Reineke, U; Schuchardt, C; Singh, A; Smerling, C; Wiessalla, S1
Ćwikła, JB; Kolasińska-Ćwikła, A; Maciejkiewicz, KM; Łowczak, A1
Boucher, JE; Sommers, R1
Blažević, A; Brabander, T; de Herder, WW; Feelders, RA; Hofland, J; Kam, BLR; Teunissen, JJM; Zandee, WT1
Aghevlian, S; Cai, Z; Hedley, DW; Lu, Y; Reilly, RM; Winnik, MA1
Gundogdu, S; Hatipoglu, E; Kabasakal, L; Kadioglu, P; Kepicoglu, H; Rusen, E1
Brusnahan, SK; Garrison, JC; Ogbomo, SM; Shi, W; Wagh, NK; Zhou, Z1
Costa, FP; de Herder, WW; Feelders, RA; Gumz, B; Kaltsas, G; Kamp, K; Kwekkeboom, DJ1
Brusnahan, SK; Garrison, JC; Jia, Y; Ogbomo, SM; Shi, W; Wagh, NK; Zhou, Z1
Guan, F; Huang, Q; Li, C; Liang, D; Wen, X; Wu, C; Wu, R; You, J; Zhao, J1
Cives, M; Soares, HP; Strosberg, J1
Cho, EH; Jung, SH; Lee, SY; Lim, JC1
Agazzi, A; Aricò, D; Bodei, L; De Cicco, C; De Simone, M; Pacifici, M; Paganelli, G; Quarna, J; Sansovini, M; Sierra, ML1
De Araújo, EB; Mengatti, J; Pujatti, PB1
de Herder, WW; Krenning, EP; Kwekkeboom, DJ1
Forrer, F; Giovacchini, G; Müller-Brand, J; Nicolas, G1
Barber, TW; Hicks, RJ; Hofman, MS; Thomson, BN1
de Herder, WW; Feelders, RA; Kamp, K; Khan, S; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; Valkema, R; van Nederveen, FH; van Schaik, E; van Vliet, EI1
Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ1
Chen, J; Hinni, K; Maecke, HR; Reubi, JC; Waldherr, C; Waser, B; Zhang, H1
Bernard, BF; Breeman, WA; de Jong, M; Krenning, EP; Valkema, R1
de Jong, M; Esser, JP; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; Valkema, R1
Bockisch, A; Broelsch, CE; Frilling, A; Hofmann, M; Mueller-Brand, J; Saner, F; Weber, F1
Anderson, TL; Atcher, RW; Nayak, TK; Norenberg, JP; Prossnitz, ER; Stabin, MG1
de Herder, WW; de Keizer, B; Feelders, RA; Kam, BL; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M1
Ahmad, N; Choi, J; Coppola, D; Gardner, NM; Kvols, LK; Kwekkeboom, DJ; Malafa, MP; Nasir, A; Strosberg, J; Teunissen, JJ1
Bakker, WH; Bernard, BF; Breeman, WA; Bugaj, JE; de Jong, M; Erion, J; Krenning, EP; Schaar, M; Schmidt, M; Srinivasan, A; van Gameren, A1

Reviews

7 review(s) available for lutetium and Pancreatic Neoplasms

ArticleYear
Overview and Current Status of Peptide Receptor Radionuclide Therapy.
    Surgical oncology clinics of North America, 2020, Volume: 29, Issue:2

    Topics: Animals; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Stomach Neoplasms

2020
Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Nuclear medicine review. Central & Eastern Europe, 2018, Volume: 21, Issue:2

    Topics: Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Radioisotopes; Receptors, Peptide; Stomach Neoplasms; Yttrium Radioisotopes

2018
Lutetium lu 177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors.
    The Medical letter on drugs and therapeutics, 2018, Sep-10, Volume: 60, Issue:1555

    Topics: Animals; Clinical Trials as Topic; Heterocyclic Compounds, 1-Ring; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Peptides, Cyclic; Protein Binding; Stomach Neoplasms

2018
Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
    Current opinion in oncology, 2016, Volume: 28, Issue:4

    Topics: Clinical Trials, Phase III as Topic; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Somatostatin; Stomach Neoplasms

2016
Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Endocrinology and metabolism clinics of North America, 2011, Volume: 40, Issue:1

    Topics: Animals; Antineoplastic Agents; Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes

2011
Targeted radiotherapy with radiolabeled somatostatin analogs.
    Endocrinology and metabolism clinics of North America, 2011, Volume: 40, Issue:1

    Topics: Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Radiation Injuries; Radioisotopes; Radionuclide Imaging; Radiotherapy; Somatostatin; Yttrium Radioisotopes

2011
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy.
    Best practice & research. Clinical gastroenterology, 2005, Volume: 19, Issue:4

    Topics: Animals; Carcinoma, Neuroendocrine; Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Patient Selection; Pentetic Acid; Peptides, Cyclic; Quality of Life; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Somatostatin; Treatment Outcome; Yttrium Radioisotopes

2005

Trials

2 trial(s) available for lutetium and Pancreatic Neoplasms

ArticleYear
Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-01, Volume: 22, Issue:13

    Topics: Adult; Aged; Female; Health Status; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Quality of Life; Receptors, Peptide; Receptors, Somatostatin; Stomach Neoplasms; Treatment Outcome

2004
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Surgery, 2006, Volume: 140, Issue:6

    Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Lutetium; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes

2006

Other Studies

26 other study(ies) available for lutetium and Pancreatic Neoplasms

ArticleYear
Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE.
    Clinical nuclear medicine, 2022, 11-01, Volume: 47, Issue:11

    Topics: Aged; Female; Humans; Intestinal Neoplasms; Lutetium; Meningeal Neoplasms; Meningioma; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Peptide; Stomach Neoplasms

2022
Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma.
    Cells, 2022, 09-24, Volume: 11, Issue:19

    Topics: Antibodies, Monoclonal; Carcinoma, Pancreatic Ductal; Copper Radioisotopes; Epitopes; Gallium Radioisotopes; Humans; Immunoconjugates; Lutetium; Mucin-1; Pancreatic Neoplasms; Radioisotopes; Technetium

2022
Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:3

    Topics: Adult; Female; Humans; Liver Neoplasms; Lutetium; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals

2020
Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy.
    BMJ case reports, 2020, Mar-31, Volume: 13, Issue:3

    Topics: Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Chromogranin A; Humans; Liver Neoplasms; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Receptors, Peptide; Remission Induction

2020
Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor.
    Cancer reports (Hoboken, N.J.), 2020, Volume: 3, Issue:5

    Topics: Bone Marrow; Chemoradiotherapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Radioisotopes; Sunitinib

2020
Lutetium oxodotreotide (
    BMC cancer, 2021, Jan-05, Volume: 21, Issue:1

    Topics: Cost-Benefit Analysis; Disease Progression; Follow-Up Studies; Humans; Intestinal Neoplasms; Lutetium; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prognosis; Quality-Adjusted Life Years; Radiopharmaceuticals; Stomach Neoplasms

2021
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018, Volume: 59, Issue:5

    Topics: Adenocarcinoma; Aged; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Drug Design; Female; Humans; Injections, Intravenous; Kidney; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Neurotensin; Retrospective Studies; Salvage Therapy; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome

2018
Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
    Clinical journal of oncology nursing, 2018, 10-01, Volume: 22, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Female; Humans; Intestinal Neoplasms; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Somatostatin; Stomach Neoplasms

2018
Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
    The Journal of clinical endocrinology and metabolism, 2019, 04-01, Volume: 104, Issue:4

    Topics: Adult; Aged; Coordination Complexes; Female; Gastrins; Glucagon; Humans; Insulin; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreas; Pancreatic Neoplasms; Quality of Life; Radiation Dosage; Radioisotopes; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Vasoactive Intestinal Peptide

2019
Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to
    Molecular pharmaceutics, 2019, 02-04, Volume: 16, Issue:2

    Topics: Animals; Antineoplastic Agents, Immunological; DNA Breaks, Double-Stranded; ErbB Receptors; Female; Humans; Lutetium; Metal Nanoparticles; Mice; Pancreatic Neoplasms; Panitumumab; Polymers; Radioimmunotherapy; Xenograft Model Antitumor Assays

2019
Von Hippel Lindau disease with metastatic pancreatic neuroendocrine tumor causing ectopic Cushing's syndrome.
    Neuro endocrinology letters, 2013, Volume: 34, Issue:1

    Topics: Adult; Carcinoma, Neuroendocrine; Cushing Syndrome; Female; Humans; Lutetium; Pancreatic Neoplasms; Peptides, Cyclic; Radioisotopes; von Hippel-Lindau Disease

2013
177Lu-labeled HPMA copolymers utilizing cathepsin B and S cleavable linkers: synthesis, characterization and preliminary in vivo investigation in a pancreatic cancer model.
    Nuclear medicine and biology, 2013, Volume: 40, Issue:5

    Topics: Animals; Biological Transport; Cathepsin B; Cathepsins; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Stability; Humans; Lutetium; Macrophages; Methacrylates; Mice; Pancreatic Neoplasms; Peptides; Proteolysis; Radioisotopes

2013
Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Endocrine-related cancer, 2013, Volume: 20, Issue:6

    Topics: Adult; Aged; Bone Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Intestinal Neoplasms; Liver Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Safety; Sirolimus; Stomach Neoplasms; Survival Rate

2013
The influence of linker length on the properties of cathepsin S cleavable (177)Lu-labeled HPMA copolymers for pancreatic cancer imaging.
    Biomaterials, 2014, Volume: 35, Issue:22

    Topics: Animals; Cathepsins; Cell Line, Tumor; Female; Humans; Lutetium; Methacrylates; Mice, SCID; Pancreas; Pancreatic Neoplasms; Tomography, Emission-Computed, Single-Photon

2014
Chemoradiation therapy using cyclopamine-loaded liquid-lipid nanoparticles and lutetium-177-labeled core-crosslinked polymeric micelles.
    Journal of controlled release : official journal of the Controlled Release Society, 2015, Mar-28, Volume: 202

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemoradiotherapy; Combined Modality Therapy; Female; Humans; Lutetium; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Radioisotopes; Tissue Distribution; Tumor Burden; Veratrum Alkaloids

2015
An assessment tumor targeting ability of (177)Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor.
    Journal of pharmacological sciences, 2016, Volume: 131, Issue:3

    Topics: Animals; Cell Line, Tumor; Cholecystokinin; Heterografts; Humans; Lutetium; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Pancreatic Neoplasms; Peptides, Cyclic; Protein Binding; Radioisotopes; Radioligand Assay; Receptors, Cholecystokinin

2016
Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC.
    Cancer biotherapy & radiopharmaceuticals, 2009, Volume: 24, Issue:6

    Topics: Adult; Aged; B-Lymphocytes; Colonic Neoplasms; Duodenal Neoplasms; Female; Humans; Ileal Neoplasms; Lung Neoplasms; Lutetium; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Yttrium Radioisotopes

2009
Radiolabeling of substance P with lutetium-177 and biodistribution study in rat pancreatic tumor xenografted nude mice.
    Cellular and molecular biology (Noisy-le-Grand, France), 2010, May-10, Volume: 56, Issue:2

    Topics: Animals; Lutetium; Mice; Mice, Nude; Neoplasm Transplantation; Pancreas; Pancreatic Neoplasms; Radioisotopes; Radionuclide Imaging; Rats; Substance P; Tissue Distribution

2010
The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2012, Volume: 38, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Duodenal Neoplasms; Fluorouracil; Humans; Lutetium; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Radioisotopes; Receptors, Peptide; Remission Induction; Research Design; Tomography, X-Ray Computed; Treatment Outcome

2012
Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:11

    Topics: Adult; Female; Humans; Hypoglycemia; Indium Radioisotopes; Insulinoma; Lutetium; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Radioisotopes; Somatostatin; Treatment Outcome

2011
Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
    Cancer research, 2004, Sep-15, Volume: 64, Issue:18

    Topics: Animals; Bombesin; Drug Stability; Humans; Indium Radioisotopes; Isotope Labeling; Lutetium; Male; Pancreatic Neoplasms; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rats; Receptors, Bombesin; Tissue Distribution; Yttrium Radioisotopes

2004
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46 Suppl 1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Humans; Lutetium; Male; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Somatostatin; Survival Analysis; Treatment Outcome; Yttrium

2005
Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
    Nuclear medicine and biology, 2007, Volume: 34, Issue:2

    Topics: Adenocarcinoma; Alpha Particles; Beta Particles; Bismuth; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Radiation; Drug Delivery Systems; Humans; Lutetium; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Treatment Outcome

2007
Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.
    European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Endocrine System Diseases; Gastrointestinal Neoplasms; Humans; Lutetium; Middle Aged; Neuroectodermal Tumors, Primitive; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radioisotopes; Retrospective Studies

2008
Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels.
    Pancreas, 2008, Volume: 36, Issue:3

    Topics: Calcitonin; Combined Modality Therapy; Diarrhea; Female; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Middle Aged; Pancreatic Neoplasms; Paraneoplastic Endocrine Syndromes; Peptides, Cyclic; Radiopharmaceuticals; Vasoactive Intestinal Peptide

2008
[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    International journal of cancer, 2001, Jun-01, Volume: 92, Issue:5

    Topics: Animals; Autoradiography; Chelating Agents; Kidney; Lutetium; Male; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Survival Rate; Tissue Distribution

2001